Literature DB >> 3930257

Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin.

E Persson, J Nordenström, P Nilsson-Ehle, L Hagenfeldt.   

Abstract

Low molecular weight heparin (LMWH) and standard heparin were given intravenously to six healthy subjects receiving a continuous infusion of Intralipid. After infusion, antifactor Xa, antithrombin II and coagulation activity (Normotest) were the same for both heparins. Activated partial thromboplastin time increased significantly, but the increase was much higher after standard heparin (+473%) than after LMWH (+48%). The increase in lipoprotein lipase activity was less pronounced after LMWH infusion. This resulted in a smaller decrease in Intralipid-triglyceride concentration and a smaller increase in both plasma FFA concentration and Intralipid fractional removal rate compared to standard heparin. This study shows that the plasma lipolytic potential of LMWH is weaker than that of standard heparin when given in doses with equipotent anticoagulation. LMWH may therefore be preferable to standard heparin as an antithrombotic agent in clinical situations where a high plasma lipolytic activity may be disadvantageous.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930257     DOI: 10.1111/j.1365-2362.1985.tb00171.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

1.  [Low molecular weight heparin: how does it modify lipid metabolism in chronic hemodialysis patients?].

Authors:  H Schneider; Y Schmitt
Journal:  Klin Wochenschr       Date:  1991-10-18

2.  Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

Authors:  D P Mikhailidis; V A Fonseca; M A Barradas; J Y Jeremy; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

3.  Structure of heparin fragments with high affinity for lipoprotein lipase and inhibition of lipoprotein lipase binding to alpha 2-macroglobulin-receptor/low-density-lipoprotein-receptor-related protein by heparin fragments.

Authors:  A Larnkjaer; A Nykjaer; G Olivecrona; H Thøgersen; P B Ostergaard
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

4.  Fatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport.

Authors:  J Peterson; B E Bihain; G Bengtsson-Olivecrona; R J Deckelbaum; Y A Carpentier; T Olivecrona
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  Interaction of size-fractionated heparins with lipoprotein lipase and hepatic lipase in the rat.

Authors:  G Liu; M Hultin; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

Review 6.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

7.  Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme.

Authors:  G Q Liu; G Bengtsson-Olivecrona; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

8.  Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme.

Authors:  Birgit Näsström; Bernd Stegmayr; Gunilla Olivecrona; Thomas Olivecrona
Journal:  BMC Nephrol       Date:  2004-11-03       Impact factor: 2.388

Review 9.  Uremic toxins and lipases in haemodialysis: a process of repeated metabolic starvation.

Authors:  Bernd Stegmayr
Journal:  Toxins (Basel)       Date:  2014-04-30       Impact factor: 4.546

10.  Tinzaparin provides lower lipid profiles in maintenance hemodialysis patients: a cross-sectional observational study.

Authors:  Ming-Hsien Tsai; Yu-Wei Fang; Jyh-Gang Leu
Journal:  ScientificWorldJournal       Date:  2014-11-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.